Using zebrafish models of leukemia to streamline drug screening and discovery

Experimental Hematology

Volumn 45, Issue , 2017, Pages 1-9

  Deveau, Adam P ^a   Bentley, Victoria L ^b   Berman, Jason N ^a,b  

^a IWK HEALTH CENTRE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYTOTOXIC AGENT; ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; CANCER RESEARCH; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENETIC ENGINEERING; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; XENOGRAFT; ZEBRA FISH; ANIMAL; GENOMICS; HUMAN; PHENOTYPE; PRECLINICAL STUDY; PROCEDURES; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEUKEMIA; PHENOTYPE; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 85004028284     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.09.012     Document Type: Review

References (71)

1. 1 Mullighan, C.G., Downing, J.R., Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol 46 (2009), 3–15.
2. 2 Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368 (2013), 2059–2074.
3. 3 Landau, D.A., Tausch, E., Taylor-Weiner, A.N., et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526 (2015), 525–530.
4. 4 Garrett-Bakelman, F.E., Li, S., Chung, S.S., et al. Divergent dynamics of epigenetic and genetic heterogeneity in relapsed acute myeloid leukemia [abstract]. Blood, 126, 2015, 306.
5. 5 Hunger, S.P., Mullighan, C.G., Acute lymphoblastic leukemia in children. N Engl J Med 373 (2015), 1541–1552.
6. 6 Löwenberg, B., Downing, J.R., Burnett, A., Acute myeloid leukemia. N Engl J Med 341 (1999), 1051–1062.
7. 7 Döhner, H., Estey, E.H., Amadori, S., et al., European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115 (2010), 453–474.
8. 8 MacRae, C.A., Peterson, R.T., Zebrafish as tools for drug discovery. Nat Rev Drug Discov 14 (2015), 721–731.
9. 9 Bowman, T.V., Zon, L.I., Swimming into the future of drug discovery: In vivo chemical screens in zebrafish. ACS Chem Biol 5 (2010), 159–161.
10. 10 DiMasi, J.A., Grabowski, H.G., Hansen, R.W., Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47 (2016), 20–33.
11. 11 Avorn, J., The $2.6 billion pill–methodologic and policy considerations. N Engl J Med 372 (2015), 1877–1879.
12. 12 Keserü, G.M., Makara, G.M., The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8 (2009), 203–212.
13. 13 Macarron, R., Critical review of the role of HTS in drug discovery. Drug Discov Today 11 (2006), 277–279.
14. 14 Real, P.J., Tosello, V., Palomero, T., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15 (2009), 50–58.
15. 15 Irvine, E., Williams, C., Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Pharmacotherapy 33 (2013), 868–881.
16. 16 Caldemeyer, L., Dugan, M., Edwards, J., Akard, L., Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep 11 (2016), 71–79.
17. 17 Rasighaemi, P., Basheer, F., Liongue, C., Ward, A.C., Zebrafish as a model for leukemia and other hematopoietic disorders. J Hematol Oncol, 8, 2015, 29.
18. 18 Ridges, S., Heaton, W.L., Joshi, D., et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 119 (2012), 5621–5631.
19. 19 Yeh, J.R., Munson, K.M., Elagib, K.E., Goldfarb, A.N., Sweetser, D.A., Peterson, R.T., Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 5 (2009), 236–243.
20. 20 Langenau, D.M., Traver, D., Ferrando, A.A., et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 299 (2003), 887–890.
21. 21 Zhao, S., Huang, J., Ye, J., A fresh look at zebrafish from the perspective of cancer research. J Exp Clin Cancer Res, 34, 2015, 80.
22. 22 Berman, J., Hsu, K., Look, A.T., Zebrafish as a model organism for blood diseases. Br J Haematol 123 (2003), 568–576.
23. 23 Sood, R., Liu, P., Novel insights into the genetic controls of primitive and definitive hematopoiesis from zebrafish models. Adv Hematol, 2012, 2012, 830703.
24. 24 Zhang, P., Liu, F., In vivo imaging of hematopoietic stem cell development in the zebrafish. Front Med 5 (2011), 239–247.
25. 25 Bertrand, J.Y., Traver, D., Hematopoietic cell development in the zebrafish embryo. Curr Opin Hematol 16 (2009), 243–248.
26. 26 Corkery, D.P., Dellaire, G., Berman, J.N., Leukaemia xenotransplantation in zebrafish - chemotherapy response assay in vivo. Br J Haematol 153 (2011), 786–789.
27. 27 Bentley, V.L., Veinotte, C.J., Corkery, D.P., et al. Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia. Haematologica 100 (2015), 70–76.
28. 28 Liu, Y., Asnani, A., Zou, L., et al. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med, 6, 2014, 266ra170.
29. 29 El-Naggar, A.M., Veinotte, C.J., Cheng, H., et al. Translational activation of HIF1 alpha by YB-1 promotes sarcoma metastasis. Cancer Cell 27 (2015), 682–697.
30. 30 Letamendia, A., Quevedo, C., Ibarbia, I., et al. Development and validation of an automated high-throughput system for zebrafish in vivo screenings. PLoS One, 7, 2012, e36690.
31. 31 Binder, V., Zon, L.I., High throughput in vivo phenotyping: The zebrafish as tool for drug discovery for hematopoietic stem cells and cancer. Drug Discovery Today: Disease Models 10 (2013), e17–e22.
32. 32 Pardo-Martin, C., Chang, T.Y., Koo, B.K., Gilleland, C.L., Wasserman, S.C., Yanik, M.F., High-throughput in vivo vertebrate screening. Nat Methods 7 (2010), 634–636.
33. 33 Stewart, A.M., Gerlai, R., Kalueff, A.V., Developing highER-throughput zebrafish screens for in-vivo CNS drug discovery. Front Behav Neurosci, 9, 2015, 14.
34. 34 Tat, J., Liu, M., Wen, X.Y., Zebrafish cancer and metastasis models for in vivo drug discovery. Drug Discov Today Technol 10 (2013), e83–e89.
35. 35 Mizgirev, I.V., Revskoy, S., A new zebrafish model for experimental leukemia therapy. Cancer Biol Ther 9 (2010), 895–902.
36. 36 Yeh, J.R., Munson, K.M., Chao, Y.L., Peterson, Q.P., Macrae, C.A., Peterson, R.T., AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 135 (2008), 401–410.
37. 37 Forrester, A.M., Grabher, C., McBride, E.R., et al. NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis. Br J Haematol 155 (2011), 167–181.
38. 38 Bill, B.R., Petzold, A.M., Clark, K.J., Schimmenti, L.A., Ekker, S.C., A primer for morpholino use in zebrafish. Zebrafish 6 (2009), 69–77.
39. 39 Feng, H., Stachura, D.L., White, R.M., et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell 18 (2010), 353–366.
40. 40 Auer, T.O., Del Bene, F., CRISPR/Cas9 and TALEN-mediated knock-in approaches in zebrafish. Methods 69 (2014), 142–150.
41. 41 Prykhozhij, S.V., Rajan, V., Gaston, D., Berman, J.N., CRISPR multitargeter: A web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. PLoS One, 10, 2015, e0119372.
42. 42 Prykhozhij, S.V., Rajan, V., Berman, J.N., A guide to computational tools and design strategies for genome editing experiments in zebrafish using CRISPR/Cas9. Zebrafish 13 (2016), 70–73.
43. 43 Armstrong, G.A., Liao, M., You, Z., Lissouba, A., Chen, B.E., Drapeau, P., Homology directed knockin of point mutations in the zebrafish tardbp and fus genes in ALS using the CRISPR/Cas9 system. PLoS One, 11, 2016, e0150188.
44. 44 Ablain, J., Durand, E.M., Yang, S., Zhou, Y., Zon, L.I., A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. Dev Cell 32 (2015), 756–764.
45. 45 Rossi, A., Kontarakis, Z., Gerri, C., et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 524 (2015), 230–233.
46. 46 Deveau, A.P., Forrester, A.M., Coombs, A.J., et al. Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98–HOXA9-induced myeloid disease. Leukemia 29 (2015), 2086–2097.
47. 47 Ma, D., Zhang, J., Lin, H.F., Italiano, J., Handin, R.I., The identification and characterization of zebrafish hematopoietic stem cells. Blood 118 (2011), 289–297.
48. 48 Benetatos, L., Vartholomatos, G., On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver. Ann Hematol 95 (2016), 1571–1582.
49. 49 Mudbhary, R., Sadler, K.C., Epigenetics, development, and cancer: zebrafish make their mark. Birth Defects Res C Embryo Today 93 (2011), 194–203.
50. 50 Conway O'Brien, E., Prideaux, S., Chevassut, T., The epigenetic landscape of acute myeloid leukemia. Adv Hematol, 2014, 2014, 103175.
51. 51 Wang, G.G., Cai, L., Pasillas, M.P., Kamps, M.P., NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 9 (2007), 804–812.
52. 52 White, R.M., Sessa, A., Burke, C., et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2 (2008), 183–189.
53. 53 Takemura, G., Fujiwara, H., Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49 (2007), 330–352.
54. 54 Cvitkovic, E., Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24 (1998), 265–281.
55. 55 Chu, T.F., Rupnick, M.A., Kerkela, R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007), 2011–2019.
56. 56 Kerkelä, R., Grazette, L., Yacobi, R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 (2006), 908–916.
57. 57 Ou, H.C., Raible, D.W., Rubel, E.W., Cisplatin induced hair cell loss in zebrafish (Danio rerio) lateral line. Hear Res 233 (2007), 46–53.
58. 58 Lee, S.K., Oh, K.H., Chung, A.Y., et al. Protective role of quercetin against cisplatin-induced hair cell damage in zebrafish embryos. Hum Exp Toxicol 34 (2015), 1043–1052.
59. 59 Trede, N.S., Langenau, D.M., Traver, D., Look, A.T., Zon, L.I., The use of zebrafish to understand immunity. Immunity 20 (2004), 367–379.
60. 60 Sharpless, N.E., INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576 (2005), 22–38.
61. 61 Howe, K., Clark, M.D., Torroja, C.F., et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 496 (2013), 498–503.
62. 62 Haldi, M., Ton, C., Seng, W.L., McGrath, P., Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9 (2006), 139–151.
63. 63 Lam, S.H., Chua, H.L., Gong, Z., Lam, T.J., Sin, Y.M., Development and maturation of the immune system in zebrafish, Danio rerio: a gene expression profiling, in situ hybridization and immunological study. Dev Comp Immunol 28 (2004), 9–28.
64. 64 Tamplin, O.J., White, R.M., Jing, L., et al. Small molecule screening in zebrafish: swimming in potential drug therapies. Wiley Interdiscip Rev Dev Biol 1 (2012), 459–468.
65. 65 Zon, L.I., Peterson, R.T., In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 4 (2005), 35–44.
66. 66 Murphey, R.D., Stern, H.M., Straub, C.T., Zon, L.I., A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem Biol Drug Des 68 (2006), 213–219.
67. 67 LeBlanc, M.A., Bettle, A., Berman, J.N., et al. Study of glycine and folic acid supplementation to ameliorate transfusion dependence in congenital SLC25A38 mutated sideroblastic anemia. Pediatr Blood Cancer 63 (2016), 1307–1309.
68. 68 North, T.E., Goessling, W., Walkley, C.R., et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447 (2007), 1007–1011.
69. 69 Veinotte, C.J., Dellaire, G., Berman, J.N., Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis Model Mech 7 (2014), 745–754.
70. 70 Wang, Y., Krivtsov, A.V., Sinha, A.U., et al. The Wnt/betacatenin pathway is required for the development of leukemia stem cells in AML. Science 327 (2010), 1650–1653.
71. 71 Goldstone, J.V., McArthur, A.G., Kubota, A., et al. Identification and developmental expression of the full complement of cytochrome P450 genes in zebrafish. BMC Genomics, 11, 2010, 643.